Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.51 USD
Change Today -0.02 / -3.77%
Volume 520.2K
DSCO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Key Developments

Discovery Labs Receives Nasdaq Notification Related To Minimum Bid Price

Discovery Laboratories, Inc. announced that, on June 29, 2015, the Company received a letter from The Nasdaq Stock Market indicating that, because the Company's common stock has not maintained a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days, the Company is no longer in compliance with Nasdaq's Listing Rule 5550(a)(2). This notice of noncompliance has no immediate impact on the continued listing or trading of the Company's common stock on the Nasdaq Capital Market. Under the Nasdaq Listing Rules, the Company has 180 calendar days ("grace period"), or until December 28, 2015, to regain compliance with the Minimum Bid Price Requirement. If during the grace period, the Company's common stock achieves a minimum closing bid price of at least $1.00 per share for a period of at least ten consecutive business days, the Company will regain compliance with the Minimum Bid Price Requirement and its common stock will continue to be eligible for listing on the Nasdaq Capital Market. If the Company does not achieve compliance with the Minimum Bid Price Requirement during the grace period, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. However, if on the last day of the grace period, the Company complies with the market value requirement for continued listing and all other listing standards for initial listing on the Nasdaq Capital Market, and indicates its intention to cure its non-compliance with the Minimum Bid Price Requirement, the Company may be eligible for an additional grace period through June 27, 2016. The Company intends to monitor the closing bid price of its common stock and, if appropriate, consider available options potentially to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.

Discovery labs Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM

Discovery labs Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Discovery Laboratories Inc. Announces Encouraging Data from Phase IIa RDS trial

Discovery Laboratories Inc. has announced encouraging data from AEROSURF Phase IIa clinical trial in premature infants with respiratory distress syndrome, or RDS. Key objectives of the study were achieved, including the primary objective of demonstrating the safety and tolerability of a single exposure of aerosolized KL4 surfactant administered in three escalating inhaled doses to premature infants 29 to 34 week gestational age and receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone, and establishing proof of concept for the Company's proprietary technology platform based on physiological data suggesting that aerosolized KL4 surfactant is being delivered into the lung of premature infants, and acceptable performance of the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU).

Discovery Labs Announces Enrollment of First Patient in AEROSURF® Phase 2A Dose Expansion Trial

Discovery Laboratories Inc. reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF®, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone. This phase is intended to expand upon the knowledge gained in the recently completed phase 2a clinical trial, the results of which were reported in mid-May 2015. The Company expects to complete this study in the fourth quarter of 2015. The recently completed phase 2a clinical trial was designed to assess the safety and tolerability of three escalating single doses of aerosolized KL4 surfactant in premature infants 29 to 34 weeks gestational age who are receiving nCPAP for RDS, compared to infants receiving nCPAP alone. All key objectives were achieved, including the primary objective of demonstrating a favorable safety and tolerability profile of AEROSURF, establishing proof of concept for the Company's proprietary technology platform based on physiological data suggesting that aerosolized KL4 surfactant is being delivered into the lung of premature infants, and acceptable performance of the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU). This next phase 2a dose expansion study is a multicenter, randomized, open-label, controlled study and is designed to evaluate the safety and tolerability of aerosolized KL4 surfactant administered in higher and repeat doses in premature infants 29 to 34 weeks GA who are receiving nCPAP for RDS, compared to infants receiving nCPAP alone. In addition to safety and tolerability, another objective of the expansion study is to continue to evaluate the physiological effects of higher and repeat dosing of aerosolized KL4 surfactant. The results of this expansion trial are expected to provide further insight and data to support the design of the planned AEROSURF phase 2b clinical program.

Discovery Laboratories Inc. Reports Top Line Data from AEROSURF® Phase 2A Clinical Trial

Discovery Laboratories Inc. reported top line data from its recently completed AEROSURF® phase 2a clinical trial in premature infants with respiratory distress syndrome. Key objectives of the study were achieved, including (1) the primary objective of demonstrating the safety and tolerability of a single exposure of aerosolized KL4 surfactant administered in three escalating inhaled doses to premature infants 29 to 34 week gestational age and receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone, and (2) establishing proof of concept for the Company's proprietary technology platform based on physiological data suggesting that aerosolized KL4 surfactant is being delivered into the lung of premature infants, and acceptable performance of the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU). AEROSURF is Discovery Labs' combination drug/device product that combines the Company's novel synthetic peptide-containing (KL4) surfactant and its proprietary aerosol delivery technologies, including the CAG, that are designed to enable efficient delivery of aerosolized KL4 surfactant. Currently, the available surfactants (animal-derived) can only be administered using endotracheal intubation with mechanical ventilation, invasive procedures that may each result in serious complications and other respiratory conditions. With AEROSURF, neonatologists potentially will be able to administer aerosolized KL4 surfactant to premature infants supported with nCPAP alone, without having to resort to invasive intubation and mechanical ventilation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $0.51 USD -0.02

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.08
AbbVie Inc $70.01 USD -0.15
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.6x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.